NADairX is a new pulmonary delivery platform designed to provide the user with consistent exposure to NAD+.

A natural molecule found in every living cell, NAD+ (nicotinamide adenine dinucleotide) supports cellular energy production and promotes DNA repair. 

The new device delivers 60 mg of inhalable NAD+ directly to the lungs, allowing rapid absorption into the bloodstream while bypassing digestive barriers that can limit oral supplementation. Each capsule contains a precisely measured dose of NAD+, supporting consistent and repeatable delivery.

NADairX was co-founded by Erin Lee, wellness entrepreneur and founder of the Touchless Wellness Association, and Iain De Havilland, longevity researcher and founder of its supporting platform, NADclinic.

The platform offers a way to help democratise access to NAD+ therapies.

The initial rollout will focus on B2B partners, including longevity clinics, wellness operators, recovery centres and fitness facilities.

Erin Lee, co-founder and CEO of NADairX, said: “Our goal was to explore whether pulmonary delivery could offer a more accessible and scalable way for people to engage with NAD+ therapies.”

Iain De Havilland, founder of NADclinic, says: “As interest in NAD+ therapies continues to grow, it’s important that we explore delivery methods that are practical, scalable and biologically credible.”